Debiopharm, ThinkingNodeLife.ai join forces to advance AI-driven cancer drug development
Debiopharm, an independent biopharmaceutical company based in Switzerland, has forged a collaborative partnership with USA's ThinkingNodeLife.ai (TNL), a pioneer in AI Digital Cells Lab, to ... Read More
Nuvation Bio receives FDA clearance for NUV-1511 IND in advanced solid tumors
In a significant stride for cancer treatment, Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company dedicated to addressing unmet needs in oncology, announced the U.S. ... Read More
Caplin Group to invest Rs 700cr in Tamil Nadu for diverse projects
Caplin Group of Companies, comprising Caplin Point Laboratories Limited and its subsidiaries Caplin Steriles Limited and Caplin One Labs Limited, has entered into a Memorandum ... Read More
ANGLE plc announces cancer diagnosis breakthrough with DNA molecular analysis
ANGLE plc, a global leader in liquid biopsy technology, has recently achieved a major breakthrough in cancer diagnostics, unveiling results from DNA molecular analysis of ... Read More
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash payment of $1.0 billion, representing a 62% ... Read More
Absci collaborates with AstraZeneca for AI-designed oncology antibody
Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, announced a groundbreaking collaboration with AstraZeneca, a global biopharmaceutical company. This partnership aims to ... Read More
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its ... Read More
Perpetual Medicines secures $8m for peptide drug discovery platform
Perpetual Medicines, a frontrunner in computational peptide therapeutics, recently announced an impressive $8 million seed financing round, spearheaded by Chengwei Capital. This significant financial injection ... Read More
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More
Curium wraps up patient enrollment in ECLIPSE trial in prostate cancer
Curium, a leading figure in the global nuclear medicine sector, has proudly announced the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE ... Read More